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Abstract
Multiple sclerosis (MS) is an autoimmune disease of the human central nervous system. It is one of the most common neu-
rological disorders around the world and there is still no complete cure for MS. Purification of a terpenoid from Capparis ovata 
was carried out and its structure was elucidated as stigmast-5,22-dien-3β-ol, myristate (3β,22E-stigmasteryl myristate; SDM) 
by NMR and mass spectral analyses. No information regarding its any health effect is available in the literature. In the present 
study, we have described its effects on inflammatory factors such as the expression levels of cytokines, chemokines and adhe-
sion molecules as well as apoptosis/infiltration and myelination in SH-SY5Y cells. The expression levels of proinflammatory 
or inflammatory cytokines and chemokines such as NF-κB1, CCL5, CXCL9, CXCL10 and HIF1A along with T-cell activating 
cytokines such as IL-6 and TGFB1 were significantly downregulated with SDM treatment. Moreover, the expression levels 
of the main myelin proteins such as MBP, MAG and PLP that are essential for healthy myelin architecture were significantly 
up-regulated. The results presented in this study strongly suggest that the SDM offers a unique possibility to be used with au-
toimmune diseases, including MS due to its activity on the manipulation of cytokines and the promotion of myelin formation.
Introduction
Multiple sclerosis (MS) is a recurring disease of the human central nervous system (CNS) 
in which repeated occurrences of inflammatory demyelination result in the development 
of distinctly demyelinated plaques of gliotic scar tissue related to varying degrees of axo-
nal loss (1,2). MS is presently viewed as an “unpredictable-complex characteristic” that is 
activated in hereditarily susceptible people by environmental components. The disease is 
likewise considered to contain an autoimmune factor where both the innate and adaptive 
systems have been involved in disease pathogenesis (3,4). It is one of the most common 
neurological disorders around the world. There is still no complete cure for MS and it 
remains entirely non-treatable disease with no effective treatment. Therefore, pharmaceu-
tical companies and scientists are still searching for new drugs (2,5,6).
 Recently, various studies portraying the valuable properties of extracts or constituents 
from plants utilized as a part of alternative and complementary treatments have been 
reported. The utilization of such extracts as complementary and alternative medicine has 
recently expanded (7,8). Furthermore, these plant extracts present an excellent source of 
drug candidates for both scientific and pharmaceutical industrial research. 
The caper (Capparis) is a native Mediterranean plant and certain species of capers have 
been cultivated as an economically important plant. It has been reported that the genus 
Capparis consists of nearly 80 species. C. ovata and C. spinosa have wide natural distri-
bution in Turkey, and they are consumed as pickles (9). In general, Capparaceae family 
members contain glucosinolates, alkaloids, and flavonoids. Caper flower buds, root bark, 
and fruits of the plant are used in folk medicine due to their analgesic, wound healing, cell 
regeneration, tonic, diuretic effects and treatment of Multiple Sclerosis (10-14). 
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The water extract of Capparis ovata has been shown to be 
used as an alternative medicine for the treatment of MS (13,14). 
For this reason, C. ovata extract was further fractionated and 
studied for additional anti-neuroinflammatory effects in SH-
SY5Y cells. Purification of the terpenoid was carried out and its 
structure was elucidated as stigmast-5,22-dien-3β-ol, myristate 
(SDM) based on 1D- and 2D-NMR and mass spectroscopic 
techniques. No information regarding its any health effect is 
available in the literature. In the present study, we have demon-
strated that SDM significantly reduces the expression of the 
genes important in inflammation in SH-SY5Y cells. We have 
described its effects on inflammatory factors such as the ex-
pression levels of cytokines, chemokines and adhesion mole-
cules as well as apoptosis/infiltration and myelination.
Materials and Methods
Plant materials, extraction and samples preparation
NMR spectra on a Varian VNMRS spectrometer operating 
at 600 MHz for1H-NMR and 150 MHz for13C-NMR (TMS as 
an internal standard) including APT, COSY, HMBC, HMQC 
spectra.
Capparis ovata Desf. parts (flowering buds, flowers and 
fruits) were supplied by Asci Murat Capers, Ice Cream, Des-
sert and Pickle Manufacturing & Export Co., Ltd. to prepare 
the extract. Fruits of C. ovata that had been collected from the 
beginning of May to the end of September in Denizli and Bur-
dur (Southern Turkey) in 2015, and identified by Dr. Mehmet 
Çiçek. A voucher specimen was deposited in the Herbarium of 
the Faculty of Science and Letters, Pamukkale University, Den-
izli, Turkey (PAMUH2012000006300). 
Fresh fruits of C. ovata (1.280 kg) were dried at room tem-
perature, cut into pieces and ground in a grinder. They were 
macerated five times for 24 h at room temperature, with di-
chloromethane/hexane (50%, v/v). After filtration, the solvents 
were evaporated to dryness under vacuum. 
Isolation and identification of stigmast-5,22-dien-3β-ol, 
myristate (3β,22E-stigmasteryl myristate; SDM)
The dichloromethane/hexane extract of fruits (CDHFr) (20 g) 
was subjected to a silica gel column (1.5 x 40 cm) and eluted 
with petroleum ether (40–60°) (5 x 150 mL), a gradient of di-
chloromethane was added  by 10 mL increments into 100 mL 
petroleum ether up to reaching 100 %. Thus, 5 x 300 mL di-
chloromethane were used, followed by acetone by 10 mL in-
crements up to 100% (5 x 200 mL) and finally, methanol was 
used by 10 mL increments up to 100% (5 x 200 mL). The sim-
ilar fractions were combined by using TLC analysis and then 
further subjected to preparative thin layer chromatography to 
yield compound 3β,22E-stigmasteryl myristate from CDHFr 
(fraction 4) and purified from the solvent system (petroleum 
ether: dichloromethane, 3:2; v/v) as 15 mg. TLC plates were 
visualized by spraying with cerium (IV) sulphate dissolved in 
10% sulphuric acid following UV light checking.
NMR spectra were recorded on a Varian VNMRS spec-
trometer operating at 600 MHz for 1H-NMR and 150 MHz for 
13C-NMR (TMS as an internal standard), mass spectrum was 
taken by ESI technique on Tandem-Triple Quadrupole MS (Zi-
vak Technology).
Cell Culture
The human neuroblastoma cell line SH-SY5Y was obtained 
from the American Type Culture Collection (ATCC, USA). 
The cells were cultured in DMEM-F12 supplemented with 10% 
FBS and 1% penicillin/streptomycin mixture in a humidified 
atmosphere of 95% air with 5% CO2 at 37°C and were subcul-
tured twice a week.
Cytotoxicity assay
SH-SY5Y cells were seeded in 96-well plates at a density of 
1×103 cells/mL culture medium. After 24-h incubation, the 
cells were treated with varying concentrations (ranging from 
4µM to 96µM) of SDM. An equal amount of medium without 
SDM was added to untreated cells (control). SDM-treated and 
control cells were incubated for 24 h at 37°C in humidified 5% 
CO2 atmosphere. Following incubation, the medium was re-
placed by 0.5% crystal violet solution (w/v; in 50% ethanol). 
Dye absorbed by live cells was extracted with sodium citrate 
(0.1 M in 50% ethanol). Absorbance was read at 630 nm. Vi-
ability was expressed as a percentage of the control, untreated 
cells. 
RNA isolation and cDNA synthesis
Total RNA was extracted from SH-SY5Y cells by using RNeasy 
Plus mini kit (Qiagen) according to the manufacturer’s instruc-
tion with slight modifications. Elution was performed with 
40µL RNase-free water. After elution, the RNA concentration 
was determined using a Nanodrop (MaestroNano micro-vol-
ume Spectrophotometer, USA), and the RNA was reverse 
transcribed using Easy Script cDNA Synthesis Kit (ABM). The 
reaction mixture was incubated for 50 min at 50⁰C followed 
by termination by heating at 5 min 85⁰C. cDNA was stored at 
-80⁰C for further use.
Quantitative RT-PCR 
Quantitative Real Time PCR (qRT-PCR) analysis was per-
formed using SYBR Green qPCR Master Mix (GM, Taiwan) 
in an Exicycler 96 Real Time Quantitative Thermal Block PCR 
System (Bioneer, Daejeon, Korea) for each gene. The mRNA 
levels of genes (APP, C1S, CCL5, CXCL9, CXCL10, GFAP, HI-
F1A, IL6, MAG, MBP, MMP9, NF-κB1, PLP, PTPN11, STAT3, 
SOD, TGFβ1, TNFα) were determined by qRT-PCR. Beta-ac-
tin was chosen from the group of housekeeping genes as the 
least varying reference gene. The qPCR using custom designed 
primers for the genes listed in Table 1.
Statistical analysis
Statistical analysis was performed using the Minitab 13 statis-
tical software package (Minitab Inc. State College, PA, USA). 
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All results were expressed as means including their Standard 
Error of Means (SEM). Comparison between groups was per-
formed using Student’s t-test, and p< 0.05 was selected as the 
level required for statistical significance. Statistical compari-
sons between three groups were assessed by one-way analysis 
of variance (ANOVA).
Results
Stigmast-5,22-dien-3β-ol, myristate (3β,22E-Stigmasteryl 
myristate = Stigmasta-5,22-dien-3β-ol, tetradecanoate)
It was isolated for the first time from the Capparaceae members 
and the structure of the compound is found to be 3β,22E-stig-
masteryl myristate (SDM). The NMR and MS data are given 
below, and the spectra are given as supplementary material.
Waxy, yellowish.1H-NMR (600 MHz, CDCl3): δ 4.60 (1H, 
m, H-3α), 5.34 (1H, brd, J= 4.1 Hz, H-6), 5.02 (m, H-23), 5.75 
(m, H-22),  2.26 (dd, J= 2.7;7.6 Hz, H-4α), 2.31 (dd, J= 6.5 Hz, 
H-4β), 0.68 (3H, s, Me-18), 1.02 (3H, s, Me-19), 0.92 (3H, d, 
J=6.5 Hz, Me-21), 0.81 (d, J=7.9 Hz, Me-27), 0.83 (d, J=6.8 
Hz, Me-29), 1.25 (s, Me-28), 0.83 (3H, d, J=6.8 Hz, Me-26), 
0.85 (3H, t, J=7.1 Hz, Me-29).13C-NMR (150 MHz, CDCl3): 
δ 173.28 (C-1′), 36.98 (C-1), 31.90 (C-2), 73.67 (C-3), 42.28 
Table 1. Primer sequences of the selected human genes
GeneBank Gene F_Sequence (5’->3’) R_Sequence(5’->3’) Tm
NM_000533 PLP GAAAGCCCTTTTCATTGCAGGA GGCTAGTCTGCTTTGTGGCT 56⁰C
NM_002834 PTPN11 GACGTTCCCAAAACCATCCA TCTTCTTCAATCCTGCGCTGT 56⁰C
NM_000600 IL6 ACTCACCTCTTCAGAACGAATTG CCATCTTTGGAAGGTTCAGGTTG 59⁰C
NM_003998 NFKB1 TCGCGCTGAGTATAAAAGCC GGCAAAGTTTCGTGGATGCG 61⁰C
NM_002416 CXCL9 GGCTCTTTCCTGGCTACTCC TCCCTGGTCCCTGTAGTGAG 61⁰C
NM_000484 APP GCCCTGCGGAATTGACAAG CCATCTGCATAGTCTGTGTCTG 61⁰C
NM_002985 CCL5 CAGTCGTCTTTGTCACCCGA AGAGCAAGCAGAAACAGGCA 62⁰C 
NM_001565 CXCL10 ACCAGAGGGGAGCAAAATCG GGAAGTGATGGGAGAGGCAG 62⁰C 
NM_004994 MMP9 GGGACGCAGACATCGTCATC TCGTCATCGTCGAAATGGGC 62⁰C
NM_002055 GFAP GTGTCAGAAGGCCACCTCAA TCAGGTCTGGGGAAATGTGC 62⁰C 
NM_000454 SOD TAAAGTAGTCGCGGAGACGG CTTCGTCGCCATAACTCGCT 62⁰C
NM_000594 TNF TGGGATCATTGCCCTGTGAG GGTGTCTGAAGGAGGGGGTA 62⁰C 
NM_002361 MAG CCAAGTAGTCCACGAGAGCTT CAGGTCCCCACGGAAGTAGT 62⁰C
NM_002385 MBP TCGGCTCACAAGGGATTCAAG TGATCCAGAGCGACTATCTCTTC 51⁰C
NM_001530 HIF1A GGCGCGAACGACAAGAAAAA GTGGCAACTGATGAGCAAGC 61⁰C
NM_001734 C1S TTTGGCATGGGTTTATGCTGA GGGTGAAGTAGAGGTGAATCCC 51⁰C
NM_000660 TGFβ1 TACCTGAACCCGTGTTGCTCTC GTTGCTGAGGTATCGCCAGGAA 51⁰C
NM_003150 STAT3 AACAGGATGGCCCAATGGAA GAAGCGGCTATACTGCTGGT 61⁰C

































(C-4), 139.69 (C-5), 122.56 (C-6), 31.88 (C-7), 36.13 (C-8), 
51.42 (C-9), 36.57 (C-10), 21.01 (C-11), 39.69 (C-12), 42.29 
(C-13), 56.67 (C-14), 24.27 (C-15), 28.23 (C-16), 56.01 (C-
17), 11.95 (C-18), 19.00 (C-19), 45.81 (C-20), 20.18 (C-21), 
130.03 (C-22), 128.02 (C-23), 49.99 (C-24), 31.90 (C-25), 
21.00 (C-26), 19.30 (C-27), 29.33 (C-28), 11.83 (C-29), 29.3 
(CH2)n. C43H74O2 APCI-MS  (m/z): 622.5 [M
+] (4), 607.5, 
448.2,  365.2, 333.2 (Fig 1).
Figure 1. Chemical structure of stigmast-5,22-dien-3β-ol, myristate.
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Effects of stigmast-5,22-dien-3β-ol, myristate on cell viability
The cytotoxicity of stigmast-5,22-dien-3β-ol, myristate (SDM) 
in SH-SY5Y cells was investigated by crystal violet staining. As 
shown in Fig. 2, SDM treatment revealed a concentration-de-
pendent cytotoxic effect on SH-SY5Y cells in a dose-dependent 
manner. The EC5 and EC10 values of the SDM were found to 
be 8 and 12µM, respectively.
Figure 2. Cytotoxicity of stigmast-5,22-dien-3β-ol, myristate (SDM) 
on SH-SY5Y cells after 24h. The results are expressed as the means 
of two independent experiments, with each experiment performed 
in triplicate.
Effects of stigmast-5,22-dien-3β-ol, myristate on multiple 
sclerosis-related genes mRNA levels
The effect of SDM on the expression of the main MS-related 
genes participating in inflammation/cytokine/chemokine, my-
elination/demyelination and T cell activation was determined 
in this study (Figs. 3–7). All of the myelination/demyelination 
genes (MAG, MBP, PLP, SOD) were significantly increased by 8 
and 12µM SDM treatment. CXCL10 and HIF1A mRNA levels 
were decreased by 8 and 12 µM SDM treatments; however, the 
reduction in mRNA levels due to 8 µM SDM treatment was not 
found to be statistically significant. Similarly, the other inflam-
mation/chemokine/cytokine gene PTPN11 was significantly 
Figure 3. mRNA expression level of the myelination/demyelination 
genes in the control and various treatment groups. *Significantly 
different from the respective control value (p<0.05).
Figure 4. mRNA expression level of inflammation/chemokine/cyto-
kine genes in the control and various treatment groups. *Signifi-
cantly different from the respective control value (p<0.05).
Figure 5. mRNA expression level of inflammation/chemokine/cyto-
kine genes in the control and various treatment groups. *Signifi-
cantly different from the respective control value (p<0.05).
Figure 6. mRNA expression level of T cell activation genes in the 
control and various treatment groups. 
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down-regulated with SDM treatments. IL6, C1S, and TGFβ1 
mRNA levels decreased slightly in response to SDM treatment 
but, while this decrease was not statistically significant. Finally, 
GFAP and MMP9 genes were downregulated with SDM treat-
ment in SH-SY5Y cells.
Discussion
Despite several officially endorsed pharmaceuticals, the treat-
ment choices in MS are restricted and no complete cure is 
presently known (15). Many individuals with MS investigate 
complementary and alternative solutions to help control their 
MS and treat their symptoms. It was reported that up to 70% 
of individuals with MS had attempted at least one CAM treat-
ment for their MS (7). Turkish patients use Capparis ovata as 
CAM treatment and it has shown to be effective in MS treat-
ment (14). To this end, we have focused on the further purifica-
tion of Capparis ovata extract focusing on the phytosterols and 
terpenoids since several terpenoids such as ginkgolide B and 
tetrahydrocannabinol are known to be effective in MS (16-19).
The anti-neuroinflammatory and immunomodulatory ac-
tivity of stigmast-5,22-dien-3β-ol, myristate were tested in SH-
SY5Y cells which are often used as in vitro models of neuronal 
functions. Although it has been shown that stigmasterol exhib-
its some anti-inflammatory responses, no effects of stigmast-
5,22-dien-3β-ol, myristate on inflammation and myelination 
have been reported (20). Therefore, we decided to evaluate the 
effect of SDM in SH-SY5Y cells at the two doses -both safe and 
exert no toxic effect- which were determined to be 8 and 12 µM. 
In order to investigate the SDM treatment could be associ-
ated with a reduced immune-inflammatory reaction, we first 
examined the modulation of some inflammatory events, such 
as the expression of chemokines or cytokines in the SH-SY5Y 
cells. The genes to be considered were selected based on the 
previous animal model of inflammatory demyelinating disease 
that is experimental autoimmune encephalomyelitis (14, 21).
First, we have studied the expression levels of proinflam-
matory or inflammatory cytokines and chemokines such as 
NFKB1, CCL5, CXCL9, CXCL10, HIF1A after SDM treatment. 
Figure 7. mRNA expression level of other groups of genes in the 
control and various treatment groups. *Significantly different from 
the respective control value (p<0.05).
The expressions of all these genes except TNF were significant-
ly downregulated with SDM as compared to control. It strongly 
suggests that SDM exhibits powerful anti-inflammatory action 
by decreasing the expression levels of the major players in in-
flammation. The expression level of CCL5, CXCL10 and HI-
F1A are upregulated in either MS patient or EAE (Experimen-
tal Allergic Encephalomyelitis) animal model (22-24). Most of 
these genes are regulated by NF-κB1 and down-regulation of 
them may bring forward that SDM may act on NF-κB1 sig-
naling pathway. It is well known that the NF-κB1 cascade inte-
grates with many immunological pathways and can therefore 
effectively modulate immune response in MS patients and ex-
ert heterogeneous risk factors for MS (25), SDM as an inhibitor 
of this cascade would be a precious candidate for treatment of 
autoimmune diseases such as MS and may regulate the lym-
phocyte activation and trafficking as does the current drugs 
used to treat MS.
Furthermore, the effect of SDM on the expression of the 
genes that play a role in T-cell activation, cell adhesion and tis-
sue infiltration or apoptosis were also determined (Figures 6 
and 7). IL6 and TGFB1 are the cytokines that are involved in 
T-cell activation which is a critical parameter for the onset of 
MS (4). The down-regulation effect of SDM on the expression 
of both IL-6 and TGFB1 along with decreased expression of the 
tissue infiltration related gene (MMP9) would be recognized 
both anti-inflammatory and immune suppressive activities. 
These results further support the anti-inflammatory activity of 
the SDM.
In addition, as shown in Figure 3, the potential role of SDM 
in myelination or remyelination was studied since MS is a de-
myelinating disease and it is an essential challenge to target not 
only the inflammatory aspect of the MS, but also its neurore-
generative issues. In this aspect, SDM exhibited exceptionally 
well myelin recovery effect since MBP, MAG, PLP and SOD 
expression levels were significantly upregulated altogether 
(Figure 3). These are the main myelin proteins and are import-
ant for healthy myelin architecture (26). The increased expres-
sion of MBP, MAG and PLP by SDM may be acknowledged as 
signals that promoting myelin re-formation and repair. Thus, 
SDM displays not only anti-neuroinflammatory activity but 
also neuroprotective and neurodegenerative effects.
In conclusion, the manipulation of cytokines and the pro-
motion of myelin formation by SDM offers a unique possibility 
to be used with autoimmune diseases, including MS. Howev-
er, due to the complexity of the cytokine networks, side effects 
may occur and further animal studies and preclinical evalua-
tions must be carried out to clarify the potency of SDM as a 
therapeutic agent.
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